|
|
Antwerp, 29 January 2021, 7:30 am
Gimv announces share buyback in the context of a share purchase plan
for its personnel
The Board of Directors of Gimv has decided, in application of Art. 7:215, §1, al. 3 of the Companies
Code, to start a share buyback program of 40,000 shares in the framework of a share purchase plan
for certain Gimv employees. Gimv... Lire le communiqué |
|
| |
|
| |
|
|
Antwerp, 19 January 2021, 14:30 CET
Gimv sells OTN Systems, a provider of telecommunication solutions
for industrial markets, to listed Belden Inc.
Gimv, coshareholders Manuardeo and management, today announce that they are selling OTN
Systems to USbased Belden Inc., a global provider of telecommunication transmission and
security solutions for corporate... Lire le communiqué |
|
| |
|
| |
|
|
Antwerp BE / Schiedam NL, 2 December 2020, 7:30 CET EMBARGO
Gimv sells Itho DaalderopClimate for Life Dutch market leader in
integrated sustainable solutions for energyneutral living in the Benelux
to Parcom
Producer Itho Daalderop and service provider Klimaatgarant today announce an important step in their
development. Gimv will sell its majority... Lire le communiqué |
|
| |
|
| |
|
|
Antwerp BE / Medfield, MA US, 30 November 2020, 8:00 AM CET
Gimv is founding investor of Kinaset Therapeutics in a USD 40m series A
round – funds used to develop novel therapeutics for respiratory
diseases
Gimv invests in Kinaset Therapeutics alongside 5AM Ventures and Atlas Venture in a USD 40m Series A
round to support the clinical development of... Lire le communiqué |
|
| |
|
| |
|
|
Antwerp/Dublin, 19 November 2020, 7:30 AM CET
Gimv invests in SynOx Therapeutics which raises EUR 37 million to
develop emactuzumab for treatment of tenosynovial giant cell tumors
Gimv is investing in newly formed SynOx Therapeutics through a Series A round of EUR 37 million along
with HealthCap, Medicxi and Forbion. SynOx will continue the development of... Lire le communiqué |
|
| |
|
| |
|
|
Anvers, le 19 novembre 2020, 7:00 CET
De bons résultats grâce à un portefeuille solide
Ladministrateur délégué Koen Dejonckheere au sujet des résultats du semestre écoulé :
« Après limportante correction subie à la fin de lexercice précédent en raison de la crise
pandémique, Gimv a réalisé un rendement de 12 % sur son portefeuille au cours du... Lire le communiqué |
|
| |
|
| |
|
|
Antwerp BE / The Hague NL / Houten NL, 22 October 2020, 17u45 CET
Gimv and founder sell Eurocept Homecare active in ’Hospitalathome‘
services and complex wound care to Mediq
Eurocept today announces an important step in its growth. Founder Mike van Woensel and Gimv sell their
stake in Eurocept Homecare to Mediq. Mediq is part of Mediq Group, a leading... Lire le communiqué |
|
| |
|
| |
